Heme/Onc fellow @ Rutgers Cancer Institute| Internal medicine @TuftsMedicalCtr | MD @JeffersonUniv| prior: Janssen Pharmaceuticals of Johnson & Johnson 🇦🇱🇺🇸
I know running clinical trials is tough but that doesn’t mean us clinicians have to accept the results as the new standard if we find the results not applicable to our current practice.
This morning at #ASCO25: @TuftsMedicine’s @MicoVasil presents in the Hematologic Malignancies Poster Session from 9 AM to noon CDT (Hall A – Posters and Exhibits).
His research focuses on teclistamab in relapsed/refractory systemic AL amyloidosis.
Being a lifelong learner isn’t about taking pride in your knowledge. It's about having the humility to know what you don’t know.
My top 23 insights from 2023 🧵
In case u missed it, this is weight loss equivalent of inventing nuclear fusion. The societal value over rest of time of achieving this much weight reduction is profound. Ongoing studies will help measure. Odds are life expectancy just increased. https://t.co/CKefJtrq1W
❗️BREAKING at @AACR#Targets21: Mirati Therapeutics has disclosed the structure of MRTX1133, their reversible KRAS G12D inhibitor. Fantastic story. Plus hints of a new pan-KRAS inhibitor. Congratulations!
In a new @NEJM study: 70% relative risk reduction in hospitalization or death with REGEN-COV monoclonal antibody cocktail with #COVID19 at high risk of severe disease.
https://t.co/oMdhRkFkJt
Here's a chest X-ray that made the radiologist gasp and reach for the phone. What could this thin grey line possibly be? The patient was a 30 yo male, no significant medical history, who had started to experience stabbing pains in his chest a few days earlier.